Join This Trial!
Caretalk keeps your information private:
This Study is Missing Information.
Login to suggest edits!
Where This Study is Located
Conducted by 3 sites, shown below.
The location of the organization could not be found.
Add a nearby landmark
to get a more accurate location
* For some sites we're missing location information. If you know where these sites are located, feel free to make a suggsetion!
Male or female, age equal to or above18 years at the time of signing informed consent
Diagnosed with T2D at least 180 days prior to the day of screening
HbA1c of 8-10% (64−86 mmol/mol) (both inclusive)
Stable daily dose(s) for 90 days prior to the day of screening of:
Any metformin formulations (equal to or above1500 mg or maximum tolerated or effective dose) alone or in combination with sulfonylureas (SU) (equal to or above half of the maximum approved dose according to local label or maximum tolerated or effective dose)
Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes
Renal impairment measured as estimated glomerular filtration rate (eGFR) value of <30 mL/min/1.73 m^2 according to Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) creatinine equation as defined by KDIGO 2012 classification
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination